New York, NY -- (SBWIRE) -- 05/14/2013 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Tranzyme, Inc. (NASDAQ:TZYM), ICON Public Limited Company (NASDAQ:ICLR), and Gilead Sciences Inc. (NASDAQ:GILD).

Wilmington, DE -- (SBWIRE) -- 04/24/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Tranzyme, Inc. (NASDAQ:TZYM), Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), and Amgen Inc. (NASDAQ:AMGN). Tranzyme, Inc.

Tranzyme Inc. (NASDAQ:TZYM) increased 6.59% and closed at $0.555 on a traded volume of 3.33 million shares. Tranzyme Pharma and Ocera Therapeutics, Inc. have entered into a definitive agreement under which Ocera will merge with a subsidiary of ...

RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based ...

Upon closing, the company will be named "Ocera Therapeutics, Inc." The merger is expected to close in the third quarter of 2013, subject to approval by a majority of Tranzyme stockholders, review by the Securities and Exchange Commission and customary ...

Westinghouse Solar Inc. (PINK:WEST) decreased 8.27% and closed at $0.0377on a traded volume of 1.59 million shares.Westinghouse Solar, Inc. has negotiated a sub-license for use of the Westinghouse Solar brand and technologies in Australia.

Arca Biopharma Inc. (NASDAQ:ABIO) jumped up 47.21% and closed at $2.90 on a traded volume of 2.35 million shares. ARCA biopharma, Inc. announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve ...

New York, NY - (NISMAGAZINE) - 5/10/2013- Neuralstem, Inc. (NYSEMKT:CUR) gained 6.45% at $1.32 after trading 1.49 million shares.

New York, NY - (NISMAGAZINE) - 4/29/2013- Swisher Hygiene, Inc. (NASDAQ:SWSH) fell 4.86% at $1.37 after trading 374,794 shares.

Tranzyme Inc.'s board has been looking into the possible sale, merger or other business combination for the company following the discontinued development of both of its two clinical-stage drug candidates.